Ticker

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director B Lynne Parshall sold 5,000 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $76.27, for a total value of $381,350.00. Following the completion of the transaction, the director owned 51,344 shares in the

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Kyle Jenne sold 4,902 shares of the company's stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $75.17, for a total transaction of $368,483.34. Following the completion of the transaction, the executive vice president owned 23,713 shares of

Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends. Volatility and Risk Ionis Pharmaceuticals has a beta

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same…

Aberdeen Group plc trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 67.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,926 shares of the company's stock after selling 58,998 shares during the